Invion Limited (ASX: IVX) has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to INV043 for the treatment of anal cancer. This recognition is more than just a regulatory tick—it represents a strategic shift in the company’s development pathway